Core Insights - The 82nd American Academy of Dermatology Annual Meeting showcased significant clinical research data on the efficacy of Zeli Mei Ben Wei Mo De cream for treating atopic dermatitis (AD) in the Chinese population, highlighting its rapid itch relief, long-lasting efficacy, and safety profile [1][6]. Research Core Findings - Rapid Itch Relief: Zeli Mei cream demonstrated significant itch relief starting from day one of treatment, with a notable improvement on day two, showing a -5.2% change in average PP-NRS on day one and -8.0% on day two compared to the placebo group [2]. - Long-term Efficacy Maintenance: A one-year study indicated a high no-recurrence rate of 70% after discontinuation of the cream, showcasing its long-term disease control capabilities [2][4]. Research Details - Study Design: The multi-center, confirmatory clinical study involved 272 patients aged 2 years and older with moderate to severe AD across over 30 locations in China, using a randomized, double-blind, placebo-controlled method [3]. - Baseline Characteristics: The majority of the study population (52.2%) were children aged 2-17 years, with an average body surface area (BSA) of approximately 15%, indicating a wide coverage of age groups and disease severity [3]. - Efficacy Data Analysis: After 8 weeks of treatment, the Zeli Mei group achieved EASI75 and IGA response rates of 54.4% and 46.2%, respectively, significantly higher than the placebo group, demonstrating its effectiveness in improving skin lesions and overall disease control [3]. Safety Analysis - Adverse Reactions Overview: Among 193 patients treated with Zeli Mei cream, common adverse reactions included folliculitis (5.7%), pain (3.1%), and pruritus (3.1%), all classified as mild to moderate, with no severe adverse events reported [5]. - Safety Conclusion: The safety profile of Zeli Mei cream is favorable, indicating its suitability for long-term use [5]. Expert Opinions and Industry Significance - Experts highlighted the promising results of Zeli Mei cream in rapid itch relief and long-term disease alleviation, with a low recurrence rate of 70%, marking a new chapter in non-hormonal treatment for AD [6][7]. - The CEO of Zedman emphasized the global potential of Zeli Mei cream and the company's commitment to innovative drug development, enhancing China's international standing in the field of innovative drug research [7].